Efficacy of intraperitoneal chemotherapy with paclitaxel targeting peritoneal micrometastasis as revealed by GFP-tagged human gastric cancer cell lines in nude mice

International Journal of Oncology

Volumn 27, Issue 3, 2005, Pages 637-644

  Ohashi, Norifumi ^a   Kodera, Yasuhiro ^a   Nakanishi, Hayao ^b   Yokoyama, Hiroyuki ^a   Fujiwara, Michitaka ^a   Koike, Masahiko ^a   Hibi, Kenji ^a   Nakao, Akimasa ^a   Tatematsu, Masae ^b  

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

Chemosensitivity; Gastric cancer; GFP; Intraperitoneal chemotherapy; Micrometastasis; Peritoneal metastasis

Indexed keywords

ANTINEOPLASTIC AGENT; CD31 ANTIGEN; GREEN FLUORESCENT PROTEIN; PACLITAXEL;

ANIMAL; ARTICLE; COMPARATIVE STUDY; DRUG SCREENING; GENETIC TRANSFECTION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; METABOLISM; METASTASIS; METHODOLOGY; MORTALITY; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; PATHOLOGY; PERITONEUM TUMOR; PLASMID; STOMACH TUMOR; SURVIVAL; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR CELL LINE;

ANIMALS; ANTIGENS, CD31; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; GREEN FLUORESCENT PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENOUS; MALE; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; PACLITAXEL; PERITONEAL NEOPLASMS; PLASMIDS; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; SURVIVAL RATE; TRANSFECTION; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 24344467491     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Landry J, Tepper JE, Wood WC, et al. Patterns of failure following curative resection of gastric carcinoma. Int J Radiat Oncol Biol Phys 19: 1357-1362, 1990.
2. Dupont JB Jr, Lee JR, Burton GR, et al. Adenocarcinoma of the stomach: review of 1,497 cases. Cancer 41: 941-947, 1978.
3. Yamada E, Miyaishi S, Nakazato H, et al. The surgical treatment of cancer of the stomach. Int Surg 65: 387-399, 1980.
4. Bando E, Yonemura Y, Takeshita Y, et al. Intraoperative lavage for cytological examination in 1,297 patients with gastric carcinoma. Am J Surg 178: 256-262, 1999.
5. Benevolo M, Mottolese M, Cosimelli M, et al. Diagnostic and prognostic value of peritoneal immunocytology in gastric cancer. J Clin Oncol 16: 3406-3411, 1998.
6. Kodera Y, Yamamura Y, Shimizu Y, et al. Peritoneal washing cytology: prognostic value of positive findings in patients with gastric carcinoma undergoing a potentially curative resection. J Surg Oncol 72: 60-65, 1999.
7. Kodera Y, Nakanishi H, Ito S, et al. Quantitative detection of disseminated free cancer cells in peritoneal washes with realtime reverse transcriptase-polymerase chain reaction: a sensitive predictor of outcome for patients with gastric carcinoma. Ann Surg 235: 499-506, 2002.
8. Nakanishi H, Kodera Y, Yamamura Y, et al. Rapid quantitative detection of carcinoembryonic antigen-expressing free tumor cells in the peritoneal cavity of gastric-cancer patients with realtime RT-PCR on the light-cycler. Int J Cancer 89: 411-417, 2000.
9. Kodera Y, Nakanishi H, Yamamura Y, et al. Prognostic value and clinical implications of disseminated cancer cells in the peritoneal cavity detected by reverse transcriptase-polymerase chain reaction and cytology. Int J Cancer 79: 429-433, 1998.
10. Yonemura Y, Endou Y, Fujimura T, et al Diagnostic value of preoperative RT-PCR-based screening method to detect carcinoembryonic antigen-expressing free cancer cells in the peritoneal cavity from patients with gastric cancer. ANZ J Surg 71:521-528,2001.
11. Nashimoto A, Nakajima T, Furukawa H, et al Randomized trial of adjuvant chemotherapy with mitomycin, Fluorouracil, and Cytosine arabinoside followed by oral Fluorouracil in serosanegative gastric cancer: Japan Clinical Oncology Group 9206-1. J Clin Oncol 21: 2282-2287, 2003.
12. Ajani JA, Mansfield PF, Janjan N, et al. Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. J Clin Oncol 22: 2774-2780, 2004.
13. Neri B, Cini G, Andreoli F, et al. Randomized trial of adjuvant chemotherapy versus control after curative resection for gastric cancer: 5-year follow-up. Br J Cancer 84: 878-880, 2001.
14. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345: 725-730, 2001.
15. Cirera L, Balil A, Batiste-Alentorn E, et al. Randomized clinical trial of adjuvant mitomycin plus tegafür in patients with resected stage III gastric cancer. J Clin Oncol 17: 3810-3815, 1999.
16. Sugarbaker PH, Yu W and Yonemura Y: Gastrectomy, peritonectomy, and perioperative intraperitoneal chemotherapy: the evolution of treatment strategies for advanced gastric cancer. Semin Surg Oncol 21: 233-248, 2003.
17. Sautner T, Hofbauer F, Depisch D, et al. Adjuvant intraperitoneal cisplatin chemotherapy does not improve long-term survival after surgery for advanced gastric cancer. J Clin Oncol 12: 970-974, 1994.
18. Yu W, Whang I, Suh I, et al. Prospective randomized trial of early postoperative intraperitoneal chemotherapy as an adjuvant to resectable gastric cancer. Ann Surg 228: 347-354, 1998.
19. Yu W, Whang I, Chung HY, et al. Indications for early postoperative intraperitoneal chemotherapy of advanced gastric cancer: results of a prospective randomized trial. World J Surg 25:985-990,2001.
20. Mochizuki Y, Nakanishi H, Kodera Y, et al. TNF-alpha promotes progression of peritoneal metastasis as demonstrated using a green fluorescence protein (GFP)-tagged human gastric cancer cell line. Clin Exp Metastasis 21: 39-47, 2004.
21. Nakanishi H, Mochizuki Y, Kodera Y, et al. Chemosensitivity of peritoneal micrometastases as evaluated using a green fluorescence protein (GFP)-tagged human gastric cancer cell line. Cancer Sci 94: 112-118, 2003.
22. Wani MC, Taylor HL, Wall ME, et al. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 93: 2325-2327, 1971.
23. McGuire WP, Rowinsky EK, Rosenshein NB, et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 111: 273-279, 1989.
24. Rowinsky EK, Cazenave LA and Donehower RC: Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst 82: 1247-1259, 1990.
25. Eiseman JL, Eddington ND, Leslie J, et al. Plasma pharmacokinetics and tissue distribution of paclitaxel in CD2F1 mice. Cancer Chemother Pharmacol 34: 465-471, 1994.
26. Innocenti F, Danesi R, Di Paolo A, et al. Plasma and tissue disposition of paclitaxel (taxol) after intraperitoneal administration in mice. Drug Metab Dispos 23: 713-717, 1995.
27. Fushida S, Furui N, Kinami S, et al. Pharmacologic study of intraperitoneal paclitaxel in gastric cancer patients with peritoneal dissemination. Gan To Kagaku Ryoho 29: 2164-2167, 2002.
28. Yonemura Y. Endou Y, Bando E, et al. Effect of intraperitoneal administration of docetaxel on peritoneal dissemination of gastric cancer. Cancer Lett 210: 189-196,2004.
29. Mohamed F, Marchettini P, Stuart OA, et al. A comparison of hetastarch and peritoneal dialysis solution for intraperitoneal chemotherapy delivery. Eur J Surg Oncol 29: 261-265, 2003.
30. Gelderblom H, Verweij J, van Zomeren DM, et al. Influence of Cremophor El on the bioavailability of intraperitoneal paclitaxel. Clin Cancer Res 8: 1237-1241, 2002.
31. Markmän M, Rowinsky E, Hakes T, et al. Phase I trial of intraperitoneal taxol: a Gynecoloic Oncology Group study. J Clin Oncol 10: 1485-1491, 1992.
32. Markman M, Brady MF, Spirtos NM, et al. Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube, and peritoneum: a Gynecologic Oncology Group Study. J Clin Oncol 16:2620-2624, 1998.
33. Nozue M, Nishida M, Todoroki T, et al. Establishment and characterization of a human scirrhus type gastric cancer cell line, GCIY, producing CA19-9. Hum Cell 4: 71-75, 1991.
34. Motoyama T, Hojo H and Watanabe H: Comparison of seven cell lines derived from human gastric carcinomas. Acta Pathol Jpn 36: 65-83, 1986.
35. Asao T, Yazawa S, Kudo S, et al. A novel ex vivo method for assaying adhesion of cancer cells to the peritoneum. Cancer Lett 78:57-62, 1994.
36. Kuniyasu H, Oue N, Wakikawa A, et al. Expression of receptors for advanced glycation end-products (RAGE) is closely associated with the invasive and metastatic activity of gastric cancer. J Pathol 196: 163-170,2002.
37. Cormack BP, Valdivia RH and Falkow S: FACS-optimized mutants of the green fluorescent protein (GFP). Gene 173: 33-38, 1996.
38. Ohtsu T, Sasaki Y, Tamura T, et al. Clinical pharmacokinetics and pharmacodynamics of paclitaxel: a 3-hour infusion versus a 24-hour infusion. Clin Cancer Res 1: 599-606, 1995.
39. Takahashi Y, Cleary KR, Mai M, et al. Significance of vessel count and vascular endothelial growth factor and its receptor (KDR) in intestinal-type gastric cancer. Clin Cancer Res 2: 1679-1684, 1996.
40. Nitta H, Munger W, Wilson E, Ralston R and Alila H: Improved in situ immunodetection of leukocytes on paraffin embedded mouse spleen. Cell Vision 4: 73-80, 1997.
41. Horak ER, Leek R, Klenk N, et al. Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet 340: 1120-1124, 1992.
42. Wada N, Otani Y, Kubota T, et al. Reduced angiogenesis in peritoneal dissemination of gastric cancer through gelatinase inhibition. Clin Exp Metastasis 20: 431-435, 2003.
43. Nakanishi H, Kobayashi K, NishimuraT, et al. Chemosensitivity of micrometastases and circulating tumor cells to uracil and tegafür as evaluated using LacZ gene-tagged Lewis lung carcinoma cell. Cancer Lett 142: 31-41, 1999.
44. Lin WC, Pretlow TP, Pretlow TG III, et al. Development of micrometastases: earliest events detected with bacterial lacZ gene-tagged tumor cells. J Natl Cancer Inst 82: 1497-1503, 1990.
45. Hoffman R: Green fluorescent protein imaging of tumour growth, metastasis, and angiogenesis in mouse models. Lancet Oncol 3: 546-556, 2002.
46. Hoffman RM: Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: a bridge to the clinic. Invest New Drugs 17: 343-359, 1999.
47. Jacquet P, Stuart OA, Dalton R, et al. Effect of intraperitoneal chemotherapy and fibrinolytic therapy on tumor implantation in wound sites. J Surg Oncol 62: 128-134, 1996.
48. Hribaschek A, Ridwelski K, Pross M, et al. Intraperitoneal treatment using taxol is effective for experimental peritoneal carcinomatosis in a rat model. Oncol Rep 10: 1793-1798, 2003.
49. Francis P, Rowinsky E, Schneider J, et al. Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot Study. J Clin Oncol 13: 2961-2967,1995.